SmallCap Sentinel: Baby Boomers and Biotech Breakthroughs

IRVINE, Calif., Aug. 1, 2007 (PRIME NEWSWIRE) -- A comprehensive report focusing on immunology and immunotherapy companies including TapImmune (OTCBB:TPIM) has been published by financial courier and is available free of charge to the general public.

The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" has been made available at and will address preeminent and emerging biotechnology companies such as Isis Pharmaceuticals, Inc. (Nasdaq:ISIS), Cell Therapeutics (Nasdaq:CTIC), Elan Corp (NYSE:ELN), and TapImmune.

A comprehensive report focusing on TapImmune and developments in immunology has also been released and is recommended reading to biotech investors.

To view the report in its entirety, please visit:

TapImmune Inc. ("TapImmune" "TPIM") is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. TPIM technologies are based on an understanding of the function of a protein "pump" within cells that is essential in the processing of tumor antigens, known as TAP. Transporters Associated with Antigen Processing (TAP) are transporters responsible for supplying tumor-associated antigens and viral antigens used in the assembly of MHC class I surface molecules. MHC class I molecules are required for the recognition and destruction of tumor cells and virus infected cells by the cellular arm of the immune system. A wide variety of metastatic cancers evade destruction by the immune system due to absent or insufficient amounts of TAP, making the tumors unrecognizable by the immune system.

TPIM's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells allowing the subsequent recognition and killing of cancer cells by the immune system. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. For access to major media coverage of TapImmune and its science:

Statements herein contain forward-looking statements and are subject to significant risks and uncertainties that affecting results. SmallCap Sentinel/ are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.

All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid 100,000 restricted common shares of TPIM and $10,000 U.S. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding the subject company.

The SmallCap Sentinel logo is available at

CONTACT: Market Pathways/StockUpTicks
         Kurt Divich, Editor
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.